Mochida Pharmaceutical Completes Early Phase II Clinical Trial of Epadel Indicated for Alzheimer's Disease.Tokyo, Japan, Dec 15, 2005 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Mochida Pharmaceutical has completed an early phase II clinical trial Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II of Epadel, which is targeted at Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. . Epadel is the company's proprietary agent used in the treatment of hyperlipemia hyperlipemia /hy·per·li·pe·mia/ (-li-pe´me-ah) hyperlipidemia. carbohydrate-induced hyperlipemia . In the trial, Mochida compared the efficacy of the agent with that of a placebo. The obtained results indicate no substantial difference between the two. The company will analyze the results in detail and determine future development strategies. Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion